RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:231031

Erythema palmare hereditarium

high confidenceDisorder

Also known as: Lane disease · Red palms disease

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

14

19.9th percentile

Trials

0

Interventional, condition-specific

Researchers

37

Distinct authors in sample

Gene link

—

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

Erythema palmare hereditarium is a rare, benign, genetic skin disorder characterized by permanent and asymptomatic erythema of the palmar and, less frequently, the solar surfaces. In most cases, it presents with sharply demarcated redness of the thenar and hypothenar eminences, as well as the palmar aspect of the phalanges, with scattered telangiectasia spots that do not cause any discomfort (pain, itching or burning) to the patient.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

erythema palmare hereditarium · lane disease

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    14 matched papers (5 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

14

14 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

14 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

5 in the last 10 years · high confidence · 19.9th percentile (publications denominator)

Phrase hits: 14 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

37

Distinct author names in 14 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Wolff H2 papers · 2001
    Papers in Europe PMC
  2. 02
    Aktas M1 paper · 2021

    Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

    Papers in Europe PMC
  3. 03
    Carolo F1 paper · 1987
    Papers in Europe PMC
  4. 04
    Dagradi V1 paper · 1987
    Papers in Europe PMC
  5. 05
    Dannepond C1 paper · 2016

    Université François-Rabelais de Tours, 60, rue du Plat-d'Étain, 37000 Tours, France; Unité de dermatologie pédiatrique, service de dermatologie, CHRU de Tours, avenue de la République, 37044 Tours cedex 9, France.

    Papers in Europe PMC
  6. 06
    Delaini GG1 paper · 1987
    Papers in Europe PMC
  7. 07
    Demir G1 paper · 2021

    Department of Dermatology, School of Medicine, Marmara University, Istanbul, Turkey.

    Papers in Europe PMC
  8. 08
    Durieux-Verde M1 paper · 2016

    Université François-Rabelais de Tours, 60, rue du Plat-d'Étain, 37000 Tours, France; Unité de dermatologie pédiatrique, service de dermatologie, CHRU de Tours, avenue de la République, 37044 Tours cedex 9, France. Electronic address: marine_821@hotmail.com.

    Papers in Europe PMC
  9. 09
    Errichetti E1 paper · 2021

    Institute of Dermatology, "Santa Maria della Misericordia" University Hospital, Piazzale Santa Maria della Misericordia, 15, 33100, Udine, Italy. enzoerri@yahoo.it.

    Papers in Europe PMC
  10. 10
    Guillot B1 paper · 2010
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Erythema palmare hereditarium" OR "Lane disease" OR "Red palms disease"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Erythema Palmare Hereditarium

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Erythema palmare hereditarium" OR "Lane disease" OR "Red palms disease"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T10:12:15.553Z